Vanderbilt Vaccine Center
VUMC chikungunya antibody set to enter clinical trial
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Researchers push forward frontiers of vaccine science
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Designing antibodies to fight the flu
Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.
VUMC scientists ‘sprint’ to find anti-Zika antibodies
Jan. 25, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Discovery could lead to neutralizing West Nile virus
Dec. 7, 2018—Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection.
Team isolates antibodies that neutralize GI bug norovirus
Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.
Poster session Friday will feature work on next-gen vaccines
Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.
Team finds potent antibodies against three Ebola viruses
Jul. 19, 2018—Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body.
A “public” target for HIV
Jun. 8, 2018—Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.
New target to stop Ebola
May. 21, 2018—A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.
Alphavirus “Achilles heel”
May. 17, 2018—Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.
Study seeking to isolate antibodies against rabies virus
Apr. 26, 2018—Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.